Leading global healthcare products company,
), has opened a Covidien Center of Innovation in Brazil (CCI
Brazil). Located in São Paulo, near the Ponte Estaiada, CCI Brazil
will brief clinicians on the latest medical technology to aid
skillful execution through a wide range of procedures that can save
and improve patient lives. Shares of Covidien rose 0.7% following
the announcement till the last trading session.
The São Paulo center sprawls across approximately 3,000 square
meters and has the infrastructure to offer 120 courses and train
2,000 healthcare professionals annually. Also, the facility offers
courses that include mechanical ventilation, monitoring of vital
signs, surgical procedures and minimally invasive surgeries.
Integrating a wide range of industry-leading surgical devices and
medical equipment, CCI Brazil offers a fully-equipped surgical lab
for minimally invasive surgeries, a laboratory for educating in
medical and hospital procedures, a simulation lab for clinical
scenario training with a human patient simulator, a research and
development lab to help health care professionals collaborate with
the R&D staff, an Anatomage touchscreen table combined with CT
imaging to help deliver unparalleled anatomical images and an
auditorium with seating capacity for 160 people and a multimedia
CCI Brazil marks Covidien's fifth training center in an emerging
market, with other centers located in China, South Korea, India and
Turkey. It is a first-of-its-kind in Latin America.
Covidien is engaged in the creation of innovative medical
solutions for better patient outcome. The innovation center will
provide advanced surgical techniques to healthcare professionals,
which will lower treatment costs and help speed up the patient
Also, Brazil being an important market for the company's global
strategies, a growing presence in the lucrative region will
favorably affect investor's sentiment.
Currently, Covidien carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the medical products industry include ICU
Medical, Inc. (
), Abaxis, Inc. (
) and AtriCure, Inc. (
). ICU Medical sports a Zacks Rank #1 (Strong Buy) while both
Abaxis and AtriCure carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
COVIDIEN PLC (COV): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis
ATRICURE INC (ATRC): Free Stock Analysis Report
To read this article on Zacks.com click here.